Acurx Pharmaceuticals (ACXP) Expected to Release Earnings on Friday

Acurx Pharmaceuticals (NASDAQ:ACXP) is expected to release its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 8:00 AM ET.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). On average, analysts expect Acurx Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acurx Pharmaceuticals Price Performance

Shares of NASDAQ:ACXP opened at $1.47 on Wednesday. The company has a market cap of $6.32 million, a PE ratio of -0.36 and a beta of -2.03. Acurx Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $8.34. The stock’s 50-day moving average is $1.53 and its 200 day moving average is $2.23.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen upgraded Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $31.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Armistice Capital LLC bought a new position in Acurx Pharmaceuticals in the second quarter worth approximately $551,000. Geode Capital Management LLC purchased a new position in shares of Acurx Pharmaceuticals in the fourth quarter worth $31,000. Jane Street Group LLC purchased a new stake in Acurx Pharmaceuticals in the 4th quarter worth $27,000. Finally, Millennium Management LLC purchased a new stake in shares of Acurx Pharmaceuticals in the fourth quarter worth about $103,000. Institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).